• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering

    Simply Wall St·12/09/2025 10:14:49
    Listen to the news
    • EyePoint, Inc. (formerly EyePoint Pharmaceuticals, Inc.) recently secured a positive safety recommendation to continue its Phase 3 DURAVYU trials and filed a prospectus supplement for a Controlled Equity Offering of up to US$200,000,000 in common stock, while a major insider modestly reduced her holdings.
    • The combination of a clean safety review for DURAVYU and a sizable at-the-market equity program highlights both the company’s clinical momentum and its need to fund a capital-intensive late-stage pipeline.
    • We’ll now examine how the DURAVYU Phase 3 safety green light reshapes EyePoint’s investment narrative and risk-reward profile.

    We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

    EyePoint Pharmaceuticals Investment Narrative Recap

    To own EyePoint, you have to believe DURAVYU can successfully reach approval and commercial adoption before the company’s cash needs become too pressing. The fresh Phase 3 safety green light directly supports the key near term catalyst of pivotal data, while the US$200,000,000 at the market offering underscores that funding risk and potential dilution remain central concerns.

    The newly filed Controlled Equity Offering is the clearest link to this update, because it frames how EyePoint might finance DURAVYU through expensive late stage trials and a future launch. For investors, the combination of a validated safety profile and ongoing equity issuance plans sharpens the tradeoff between clinical opportunity and the risk of prolonged losses and shareholder dilution.

    Yet behind the encouraging DURAVYU progress, investors should be aware that prolonged minimal revenue and rising operating losses could still...

    Read the full narrative on EyePoint Pharmaceuticals (it's free!)

    EyePoint Pharmaceuticals' narrative projects $146.7 million revenue and $34.1 million earnings by 2028. This requires 41.4% yearly revenue growth and a $209.5 million earnings increase from $-175.4 million today.

    Uncover how EyePoint Pharmaceuticals' forecasts yield a $34.42 fair value, a 93% upside to its current price.

    Exploring Other Perspectives

    EYPT 1-Year Stock Price Chart
    EYPT 1-Year Stock Price Chart

    Simply Wall St Community members currently place EyePoint’s fair value between US$10.11 and US$34.42, across 2 independent views that reflect very different expectations. Set against this wide range, the company’s reliance on a single lead asset and ongoing need for fresh capital highlight why you may want to compare several viewpoints before forming an opinion.

    Explore 2 other fair value estimates on EyePoint Pharmaceuticals - why the stock might be worth 43% less than the current price!

    Build Your Own EyePoint Pharmaceuticals Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Contemplating Other Strategies?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.